Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Mon, 12/19/16 - 11:56 am
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Endpoints
Wed, 12/14/16 - 09:18 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
What Happened in Biotech in 2016?
Motley Fool
Tue, 11/22/16 - 09:57 pm
biotech
M&A
biosimilars
IPOs
Editas Medicine
CRISPR Therapeutics
Pfizer
Medivation
Celgene
Juno Therapeutics
Sarepta Therapeutics
Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sun, 11/13/16 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
Trump presidency could prove a salve for pharma merger deals
Yahoo/Reuters
Fri, 11/11/16 - 09:45 am
Donald Trump
M&A
Pfizer
Valeant Pharmaceuticals
biotech
Sarepta Therapeutics
Tesaro
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
Sat, 11/5/16 - 01:25 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA official warns other drug makers not to copy Sarepta
Stat/Pharmalot
Thu, 10/20/16 - 08:16 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Mon, 10/17/16 - 11:41 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Major US insurer snubs Sarepta's Duchenne drug
BioPharma Dive
Mon, 10/10/16 - 09:18 am
Anthem
insurerrs
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Yahoo/Benzinga
Tue, 10/4/16 - 03:58 pm
Sarepta Therapeutics
Europe
Duchenne Muscular Dystrophy
Summit Therapeutics
ezutromid
Top 6 Biopharma Gainers of the Past Week
24/7 Wall St
Tue, 10/4/16 - 10:20 am
Catabasis
Sarepta Therapeutics
Anavex
Biogen
Array Biopharma
GW Pharma
The Woman Behind Sarepta Therapeutics' Success
Motley Fool
Mon, 09/26/16 - 09:38 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Kyndrisa
FDA
Janet Woodcock
Sarepta quickly lays out manufacturing, launch plans after delayed approval of Duchenne MD drug
Fierce Pharma
Sat, 09/24/16 - 01:32 pm
Sarepta Therapeutics
Kyndrisa
Duchenne Muscular Dystrophy
FDA approval in hand, Sarepta plans for future studies
BioPharma Dive
Fri, 09/23/16 - 09:44 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Kyndrisa
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Fri, 09/23/16 - 09:35 am
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
FDA commissioner calls for Sarepta drug study to be retracted
Stat/Pharmalot
Thu, 09/22/16 - 12:18 pm
FDA
Sarepta Therapeutics
Robert Califf
Duchenne Muscular Dystrophy
eteplirsen
Sarepta's New Drug May Make It a Takeover
Investopedia
Wed, 09/21/16 - 10:50 pm
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
M&A
Sarepta, Patients Win - But What Of Regulatory Oversight?
Seeking Alpha
Tue, 09/20/16 - 11:10 am
Sarepta Therapeutics
regulatory
Duchenne Muscular Dystrophy
FDA
eteplirsen
Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
Stat/Pharmalot
Tue, 09/20/16 - 09:49 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
drug pricing
eteplirsen
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »